Physician profile
Iris Marie Otani
NPI 1285925990
$18,076.89
in general payments reported to CMS, 2019-2025
12 companies · $8,550 in 2025
The $8,550 reported for 2025 was more than what 90% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $744 · 2020: $40.82 · 2021: $2,025 · 2022: $140 · 2023: $4,277 · 2024: $2,300 · 2025: $8,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,050 · Grant: $4,500 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,000 · Honoraria: $300 · Food and Beverage: $262 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,050.00 |
| Grant | $4,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,000.00 |
| Honoraria | $300.00 |
| Food and Beverage | $262.12 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $8,543.83 | 2019-2025 | |
| Grifols Shared Services North America, INC. | $6,050.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,800.00 | 2021 | |
| Glaxosmithkline, LLC. | $473.55 | 2019-2020 | |
| Csl Behring | $432.53 | 2021-2024 | Hizentra |
| Biocryst US Sales Co., LLC | $277.07 | 2022-2023 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $233.72 | 2019 | |
| Abbott Laboratories | $125.15 | 2023 | Jeti |
| Kaleo, INC. | $92.05 | 2021 | |
| Optinose US, INC. | $18.16 | 2019 | |
| Shire North American Group INC | $15.56 | 2019 | |
| Pfizer INC. | $15.27 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iris Otani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.